That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19

Remdesivir is a nucleoside antiviral recently studied in several randomized trials for treatment of COVID-19. The available observational and prospective data are conflicting, requiring clinicians to critically evaluate and reconcile results to determine patient populations that may optimally benefi...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis, Matthew R., McCreary, Erin K., Pogue, Jason M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348566/
https://www.ncbi.nlm.nih.gov/pubmed/32651941
http://dx.doi.org/10.1007/s40121-020-00318-1
Descripción
Sumario:Remdesivir is a nucleoside antiviral recently studied in several randomized trials for treatment of COVID-19. The available observational and prospective data are conflicting, requiring clinicians to critically evaluate and reconcile results to determine patient populations that may optimally benefit from remdesivir therapy, especially while drug supply is scarce. In this review, we analyze pertinent clinical remdesivir data for patients with COVID-19 from January 1, 2020, through May 31, 2020.

Ejemplares similares